Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

Using a pyrimidine-2,4,6-trione motif as a zinc-binding group, a series of selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) was discovered. Optimization of initial lead 1 resulted in a potent inhibitor (51), with an IC(50) of 2 nM in a porcine TACE assay. To the best of our knowledge, compound 51 and related analogues represent first examples of non-hydroxamate-based inhibitors of TACE with single digit nanomolar potency.

[1]  H Brandstetter,et al.  The 1.8-Å Crystal Structure of a Matrix Metalloproteinase 8-Barbiturate Inhibitor Complex Reveals a Previously Unobserved Mechanism for Collagenase Substrate Recognition* , 2001, The Journal of Biological Chemistry.

[2]  G. Le,et al.  Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. , 2005, Current medicinal chemistry.

[3]  P. Darke,et al.  HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity. , 1992, Journal of medicinal chemistry.

[4]  C. Blobel,et al.  Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). , 2000, The Biochemical journal.

[5]  Chen Lihua,et al.  Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity Relationships , 2002 .

[6]  J. Castellano,et al.  Reaction of 4-acylaminomethylpyridine N-oxides with 5-monosubstituted barbituric acids in presence of acetic anhydride , 1987 .

[7]  R. Palermo,et al.  Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[8]  D. Miller,et al.  Improved method for the Wacker oxidation of cyclic and internal olefins , 1990 .

[9]  M. Covington,et al.  The fate of pro-TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. , 1997, Journal of immunology.

[10]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[11]  Chen Lihua,et al.  Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo , 2001 .

[12]  D. Danley,et al.  Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. , 2005, Bioorganic & medicinal chemistry letters.

[13]  David J Nelson,et al.  Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling. , 2003, Chemistry & biology.

[14]  R Crowther,et al.  X‐ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin , 2001, Protein science : a publication of the Protein Society.

[15]  R. Reich,et al.  Recent non-hydroxamate matrix metalloproteinase inhibitors , 2005 .

[16]  K. Appelt,et al.  Matrix Metalloproteinase Inhibitors for Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[17]  M. Covington,et al.  Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme. , 2005, Bioorganic & medicinal chemistry letters.

[18]  H. Krell,et al.  Pyrimidine-2,4,6-Triones: A New Effective and Selective Class of Matrix Metalloproteinase Inhibitors , 2001, Biological chemistry.

[19]  G. Davis,et al.  A microplate assay specific for the enzyme aggrecanase. , 2003, Analytical biochemistry.